Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study

被引：0

作者：

Kosuke Ebina

Motomu Hashimoto

Wataru Yamamoto

Toru Hirano

Ryota Hara

Masaki Katayama

Akira Onishi

Koji Nagai

Yonsu Son

Hideki Amuro

Keiichi Yamamoto

Yuichi Maeda

Koichi Murata

Sadao Jinno

Tohru Takeuchi

Makoto Hirao

Atsushi Kumanogoh

Hideki Yoshikawa

机构：

[1] Osaka University,Department of Orthopaedic Surgery

[2] Graduate School of Medicine,Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine

[3] Kyoto University,Department of Health Information Management

[4] Kurashiki Sweet Hospital,Department of Respiratory Medicine and Clinical Immunology

[5] Osaka University Graduate School of Medicine,The Center for Rheumatic Diseases

[6] Nara Medical University,Department of Rheumatology

[7] Osaka Red Cross Hospital,Department of Rheumatology and Clinical Immunology

[8] Kobe University Graduate School of Medicine,Department of Internal Medicine (IV)

[9] Osaka Medical College,First Department of Internal Medicine

[10] Kansai Medical University,Department of Medical Informatics

[11] Wakayama Medical University Hospital,undefined

来源：

Arthritis Research & Therapy | / 21卷

关键词：

ANSWER cohort; Biological disease-modifying antirheumatic drugs; Discontinuation; Rheumatoid arthritis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 180 条

[1]

Du Pan SM(2009)Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis Arthritis Rheum 61 560-568

[2]

Dehler S(2016)Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry Arthritis Care Res (Hoboken) 68 432-439

[3]

Ciurea A(2010)Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry Arthritis Rheum 62 22-32

[4]

Ziswiler HR(2015)Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab Ann Rheum Dis 74 354-360

[5]

Gabay C(2016)Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases Rheumatology (Oxford) 55 523-534

[6]

Finckh A(2017)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Ann Rheum Dis 76 960-977

[7]

Favalli EG(2004)Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues Ann Rheum Dis 63 ii13-iii7

[8]

Pregnolato F(2014)Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies Rheumatology (Oxford) 53 1664-1668

[9]

Biggioggero M(2015)Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry Rheumatology (Oxford) 54 1664-1672

[10]

Becciolini A(2015)Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry Rheumatology (Oxford) 54 2156-2165

← 1 2 3 4 5 6 7 8 9 10 →